Difference between revisions of "Team:ETH Zurich/Design"

Line 42: Line 42:
 
                     of IBD. The current main issue is thus investigation in order to confirm and to establish which microbiota
 
                     of IBD. The current main issue is thus investigation in order to confirm and to establish which microbiota
 
                     extending or shrinking can be associated with iBD.-->
 
                     extending or shrinking can be associated with iBD.-->
<p>Inflammatory bowel disease (IBD) is an insufficiently understood world-wide problem, and only invasive diagnostic tools such as colonoscopy or biopsy are currently available.</p>
+
<p>Inflammatory bowel disease (IBD) is an insufficiently understood chronic disease, whose increasing incidence, lack of proper treatment and diagnostic methods make it an urgent problem to solve <b>[CITATION NEEDED]</b>. The current methods for diagnosing IBD mainly rely on endoscopies, which are invasive and do not allow to properly characterize the microbiome of patients, believed to be implicated in pathogenesis.</p>
<p>We designed an alternative solution for in vivo analysis, using hydrogel-encapsulated E. coli, containing (i) a biological AND gate which allows our system to associate two disease markers present in the gut, (ii) a switch acting as memory, which is flipped from 0 to 1 if both markers are detected, and (iii) a reporter to be readout later in a laboratory, providing information about the detected biomarkers. </p>
+
<p>One major challenge in synthetic biology is the difficulty to combine modular frameworks into higher order networks that are reliably reproducible. We designed our circuit as interchangeable, easily tuneable parts. This allows multiplexing, one of our circuit’s major advantages.</p>
+
<p>Therefore, Pavlov's coli is the best solution for a non-invasive, modular, multiplexing, in vivo tool to investigate IBD’s unknown causes.</p>
+
  
                </p>
+
<p>We designed an alternative solution for <i>in vivo</i> diagnosis, using hydrogel-encapsulated Pavlov's coli. In order for Pavlov's coli to efficiently gather information on important aspects of IBD, such as inflammation and microbiome composition, we designed our system such that it consists of:</p>
            </div>
+
  
 +
<ol>
 +
<li>A biological AND gate that allows our system to associate known IBD markers present in the gut.</li>
 +
<li>A switch acting as memory, which is irreversibly flipped from "OFF" to "ON" if both markers are simultaneously detected by the AND gate. This switching mechanism renders a reporter (GFP, see later) sensitive to one of the two biomarkers previously encountered by our logic AND gate.</li>
 +
<li>Information sensed by the AND gate is stored (remembered) by the reporter via the switching mechanism and can be read-out later in a laboratory. This conditional activation of our reporter justifies the name of our diagnostic tool - Pavlov's coli.</li>
 +
</ol>
  
 +
<p>
 +
The encapsulation should allow for diffusion of molecules, while preventing our bacteria from colonizing the gut, therefore providing a non-invasive tool, which does not disrupt the microbiome.
 +
</p>
  
              <div class="image_box full_size">
+
<div class="image_box full_size" id="fig1">
                     <a href="https://2016.igem.org/File:T--ETH_Zurich--model_structure.svg">
+
                     <a href="https://2016.igem.org/File:T--ETH_Zurich--model_structure.png">
                         <img src="https://static.igem.org/mediawiki/2016/4/44/T--ETH_Zurich--model_structure.svg">
+
                         <img src="https://static.igem.org/mediawiki/2016/1/15/T--ETH_Zurich--model_structure.png">
 
                     </a>
 
                     </a>
                     <p><b>Figure 1:</b> Schematic view of the model structure.</p>
+
                     <p><b>Fig. 1:</b> Structure of Pavlov's coli's genetic circuit. (1) The sensor module comprises an AND gate which associates an inflammation marker with a candidate marker, representative of microbiome composition. (2)  The switch module consists of an irreversible genetic switch. (3) The reporter module can be used to retrieve information about the biomarkers sensed by our AND gate.</p>
 
                 </div>
 
                 </div>
 +
 +
<p>
 +
An additional feature of our system is that it allows for multiplexing, meaning processing multiple signals through one channel: in our system, the reporter module (3) is activated by one of the two markers also required to activate the sensor module, i.e. the AND gate (1) (see <a href="#fig1">Fig. 1</a>). The architecture of our system has the following implication: a suite of bacterial populations, each responsive to different IBD-relevant candidate markers (e.g. different AHL molecules, lactate, etc.) as well as to an inflammation marker (e.g. NO), can be engineered, complexed together and administered to a patient; upon recovery, re-exposure of faecal samples to a previously encountered biomarker can be read out through our reporter module (see <a href="#fig2">Fig. 2</a>).
 +
</p>
 +
 +
<div class="image_box full_size" id="fig2">
 +
<a href="https://2016.igem.org/File:T--ETH_Zurich--multiplexing.png">
 +
                        <img src="https://static.igem.org/mediawiki/2016/5/58/T--ETH_Zurich--multiplexing.png">
 +
                    </a>
 +
                    <p><b>Fig. 2:</b>Mode of action of Pavlov's coli. Step 1: After administration of our bacteria, biological markers can be sensed in the gut through a logical AND gate; the event is memorized through a switching mechanism. Step 2: Following excretion and retrieval of our bacteria, the memory can be read-out by exposing the samples containing our bacteria to a host of IBD-relevant candidate markers. </p>
 +
</div>
 +
 +
<p>
 +
Therefore, Pavlov's coli holds promise as a non-invasive, modular, multipleable, <i>in vivo</i> diagnostic tool for IBD investigation.
 +
</p>
  
  
<!--            <div class="image_box full_size" ">
 
                <a href="https://2016.igem.org/File:T--ETH_Zurich--ElectricalSchematic">
 
                    <img src="https://static.igem.org/mediawiki/2016/c/c2/T--ETH_Zurich--ElectricalSchematic.svg">
 
                </a>
 
                <p>Figure 1: Abstract View</p>
 
            </div>
 
-->
 
       
 
                <h3>REQUIREMENT</h3>
 
                <p>
 
                    In order to carry this investigation, we need a factor specific to inflammation. Here, we choose Nitric Oxide, which is present
 
                    in the gut when there are lesion and inflammation. We also need a proper microbiota marker. Each microbiota
 
                    naturally produces specific AHL. We thus chose AHL as a microbiota specific marker. Finally, we also
 
                    need a reporter. We chose Mnectarine a redish fluorescent protein, that will be expressed in case of
 
                    absence of associated inflammation with the microbiota, and GFP expressed in case a match between one
 
                    specific microbiota and inflammation is found.
 
                </p>
 
         
 
  
            <div class="sec white">
 
                <h3>SYSTEM</h3>
 
                <p>
 
                    As stated before, current diagnosis tools in IBD involve invasive solution such as colonoscopy and biopsy.  And because of the lack of information regarding IBD causes, and the lack of reliability when analysing samples in vitro, research stagnates. Therefore an adaptive learning tool for in vivo diagnostic and investigation was designed. Our system is composed of a logic AND gate, a switch and a second AND gate. The switch acts as a memory bit that can be flipped from 0 to 1 when it detects both inflammation and a specific microbiota disbalance through the AND gate. We currently developed three different possible switches, based on integrase kinetic, CRISP/Cas9 and the recently discovered CRISP/Cpf1 complex. Our first AND gate sensor is sensitive to both microbiota specific AHL, and inflammation marker NO. A later version allow us to sense lactate, as recent studies tends to demonstrate its role in heavy case of IBD in children. For minimal system disruption, we chose E.Coli which is native to gut microbiota. A future improvement would be to transfer this circuit into a Lactobacillus since they are also native and non pathogenic.
 
 
                 </p>
 
                 </p>
 
             </div>
 
             </div>
 +
<div>
  
 +
<h3>Sensing in the gut</h3>
  
        </div>
+
<p>One major challenge in synthetic biology is the difficulty to combine modular frameworks into higher order networks that remain reliable. We designed our circuit as interchangeable, easily tunable parts, each of which is backed by a computer model and experimental data.</p>
    </div>
+
  
 +
<p>
 +
IBD is normally accompanied by severe inflammation of the intestine. Several sources in the literature report on a sharp increase in Nitric Oxide (NO) levels in inflamed areas.  Based on this, we chose to incorporate a sensor for NO as part of a logic AND gate in our engineered bacteria<sup>[1]</sup>.
 +
</p>
  
 +
<p>
 +
Along with the presence of NO, Pavlov's coli's logic gate requires a second input in order to activate an irreversible switch (see <a href="#fig1">Fig. 1</a>; also, see section below). As the second input, we chose a marker which can provide information on microbiome composition: AHL. A number of AHLs have been found to be informative as to specific functions (e.g. biofilm formation) and microbiome composition <sup>[2]</sup>. <b>(GIVE EXAMPLE OF AHL)</b>
 +
</p>
  
 +
<p>
 +
In an alternative design, we chose to replace the AHL sensor with lactate sensor. In an interview with an expert on IBD, Prof. Lacroix <b><a href="">(LINK TO HP PAGE)</a></b>, we discussed the potential of bacterial metabolites as an alternative microbiome marker. One such a candidate turned out to be lactate, which is produced and metabolized by different bacteria in the gut. Although it is not as informative as AHL to the end of microbiome characterization, there is a strong interest in developing methods for lactate detection in the gut. Due to its nature as an intermediate metabolite, it is currently not possible to measure lactate concentrations in fecal samples of patients, adding appeal to the development of Pavlov's coli.
 +
</p>
 +
</div>
 +
</div>
 +
</div>
  
    <div class="sec light_grey" id="systemoverview">
+
<div class="sec light_grey" id="systemoverview">
        <div>
+
<div>
            <h1>SYSTEM OVERVIEW</h1>
+
        </div>
+
    <div>
+
            <div class="image_box full_size">
+
                <a href="https://2016.igem.org/File:T--ETH_Zurich--ModularView.svg">
+
                    <img src="https://static.igem.org/mediawiki/2016/d/dd/T--ETH_Zurich--ModularView.svg">
+
                </a>
+
                <p><b>Figure 2:</b> System Overview</p>
+
            </div>
+
  
  
 
             <div class="sec light_grey">
 
             <div class="sec light_grey">
  
                <h2>DESIGN MOTIVATION</h2>
+
<h2>DETAILED IMPLEMENTATION</h2>
<p>One major challenge in synthetic biology is the difficulty to combine modular frameworks into higher order networks that are reliably reproducible.We designed our circuit to be as modular as possible. As the interest of this genetic circuit mainly lays when multiplexing is possible, we designed it such that you can associate any candidate signal just by changing the promoter. Thus, constructing a simple library of <i>AHL</i>, you can create a library of E. Coli capable to sense a wide range of microbiota signals.
+
Moreover, our model shows that the system is easily tunable playing with <i>NorR</i>,<i> Esar</i>, and <i>integrase</i> production and degradation rates to fit to the required range of detection, and thus would be the best solution for a modular multiplexing investigation tool.
+
</p>
+
                <h3>INPUTS SENSOR</h3>
+
                <p>
+
                    We need a <i>NO</i> sensor and a <i>AHL</i> sensor. Later we will also need a Lactate sensor, as recent researches tend to asses that lactate is present in extremely high quantity in some heavy case of IBD in children. Our input sensor is composed of a PnorV promoter associated with esaboxes situated downstream the promoter and upstream the reporter gene. In an improved version of this sensor, the esabox (to which EsaR can bind and act as a roadblock , preventing gene transcription) will be put in different place around the PnorV promoter. The idea is to see if competitive binding can bring better result than traditional independent gene activation and inhibition. More over it is known that PnorV activation mechanism under <i>NO/NorR </i>binding involves DNA looping aroung the promoter. As a consequence, a low efficiency of <i>EsaR</i> road block behavior is expected as the looping could prevent it from binding to the esaboxes.
+
                </p>
+
            </div>
+
  
            <div class="sec light_grey">
 
                <h3>SWITCH</h3>
 
                <p> We currently developed three different possible switches, based on integrase kinetic, <i>CRISP/Cas9</i> and the recently discovered <i>CRISP/Cpf1</i> complex. When both <i>NO</i> and <i>AHL</i> are present the hybrid promoter is activated and lead to <i>intregrase</i> protein production. <i>Intregrase</i> is a protein that is capable of binding to a particular DNA sequence referred as <i>AttP</i> and <i>AttD</i>. After binding the DNA sequence is cut and inverted. The switch acts here as a memory bit that can be flipped  from 0 to 1 in an irreversible way. The flipped sequence contains a constitutive promoter associated with esaboxes, and thus negatively regulated by <i>EsaR</i>.
 
                   
 
                </p>
 
            </div>
 
  
  
 +
<p>
 +
Our system is composed of a logic AND gate, a switch and a reporter, behaving together as an associative learning circuit.
 +
</p>
  
            <div class="sec light_grey">
+
<p>
                <h3>REPORTER</h3>
+
The AND gate is composed of the P<sub>norV</sub> promoter and an operator. The promoter can be activated by NorR upon its binding with NO. In the absence of NO NorR behaves as a repressor. The operator is either an esabox, for AHL sensing, or LldO, for lactate sensing. These operators are repressed by EsaR and LldR respectively and repression is relieved upon binding of AHL or lactate respectively (see <a href="#fig3">Fig. 3</a>). The modular nature of our system allowed us to easily exchange the esabox with LldO, through one site-directed mutagenesis.  
                <p> On each side of the flipped sequence are placed a <i>mNectarine</i> and a <i>GFP</i> gene respectively. Depending of the flipping state of the DNA sequence, the cell produces either <i>mNectarine</i> of <i>GFP</i>. As explained above this gene expression is regulated by ,<i>EsaR</i>. Thus once the DNA is switched, the cell produces <i>GFP</i> if <i>AHL</i> is present in the medium.
+
</p>
                </p>
+
            </div>
+
  
 +
<p>
 +
The switch module, under the control of the AND gate, is responsible for flipping a reporter cassette irreversibly. We have designed three different switches, based on integrases[3], CRISPR/Cas9[4] and a novel genetic switch based on the recently discovered CRISPR/Cpf1[5]<b>(see Fig. and LINK) </b>
 +
</p>
  
        </div>
+
<p>
    </div>
+
The reporter module can drive expression of two different fluorescent proteins. In its default OFF state, i.e. prior to AND gate activation, the module expresses the orange fluorescent protein mNectarine under control of an operator (esabox or LldO). Upon successful flipping, activation of the operator results in GFP expression (see <a href="#fig3">Fig. 3</a>). This mechanism is what makes multiplexing possible. Note that several reporter plasmids are present in the cell and the fraction of flipped cassettes can give us quantitative information on the signal intensity of the inputs activating the AND gate (link to switch modeling page).
 +
</p>
  
    <div class="sec white" id="geneticcircuit">
+
<p>
        <div>
+
We chose <i>E. coli</i> as a host organism because it is easy to manipulate and engineer. In future the system could be transferred into a <i>Lactobacillus acidophilus</i> or <i>Lactococcus lactis</i> host, which are regarded as safe to ingest, this was recommended to us by Prof. Gerhard Rogler <b><a href="">(LINK TO HP PAGE)</a></b>.
            <h1>GENETIC CIRCUIT</h1>
+
</p>
        </div>
+
        <div>
+
  
            <div class="image_box full_size" style="max-width: 900px;">
+
<div class="image_box full_size" id="fig3">
                <a href="https://2016.igem.org/File:T--ETH_Zurich--GeneticCircuit.png">
+
<a href="https://2016.igem.org/File:T--ETH_Zurich--ModularView.svg">
                    <img src="https://static.igem.org/mediawiki/2016/3/32/T--ETH_Zurich--GeneticCircuit.png">
+
                        <img src="https://static.igem.org/mediawiki/2016/d/dd/T--ETH_Zurich--ModularView.svg">
                </a>
+
                    </a>
                <p><b>Figure 3:</b> Genetic Circuit</p>
+
                    <p><b>Fig. 3:</b>Structure of our genetic circuit for IBD diagnosis. Note how NO and AHL are both necessary to express a molecular switch (here: Bxb1) which in turn is responsible for flipping a reporter cassette to its ON state, i.e. GFP can be expressed upon induction with AHL. Note that failure to activate the AND gate would result in mNectarine expression upon induction with AHL.</p>
            </div>
+
</div>
  
 +
</div>
 +
</div>
 +
</div>
  
            <div class="sec white">
 
                <h2>NO SENSOR</h2>
 
                <p>
 
                    We use here the PnorV promoter, specific to <i>NO</i> sensing. We also use a constitutively produced <i>NorR</i> protein. <i>NorR</i> exist under
 
                    a dimer form in the cell. Each dimer is able to bind to the 3 binding site present on PnorV. Then those
 
                    three dimer assemble in a hexameric ring like structure. When <i>NO</i> is present in the medium, it binds to
 
                    the structure and activate the promoter.
 
                </p>
 
            </div>
 
  
            <div class="sec white">
+
<div class="sec white" id="conclusions">
                <h2>AHL SENSOR</h2>
+
                <p>
+
                    In addition to the PnorV promoter, we had downstream esaboxes. Esar is constituvely produced in our bacteria. Just like <i>NorR</i>
+
                    it exists as a dimer in the cell. The dimer form binds to the esaboxes forming a roadblock and unabling
+
                    gene transcription when <i>NO</i> only is present. When <i>AHL</i> enter the cell it binds to the <i>EsaR</i> dimer and free
+
                    the promoter, allowing transcription.
+
                </p>
+
            </div>
+
  
            <div class="sec white">
+
<div>
                <h2>LACTATE SENSOR</h2>
+
                <p>
+
                    Recent studies highlighted the fact that Lactate seems to be over-present in some very heavy case of IBD, especially in children.
+
                    Thus it is also interesting to investigate the role of Lactate in IBD occurrences. We uses here a modified
+
                    version of the Plac promoter. two <i>LldR</i> binding sites O1 and O2 are situated upstream the promoter. <i>LldR</i>
+
                    and <i>LldD</i> (<i>Lactate</i> -> <i>Pyruvate</i> catalyst) are constitutively produced. in absence of <i>Lactate</i>, <i>LldR</i> binds
+
                    to O1 and O2 forming a DNA loop and preventing transcription. When Lactate enter the system, it binds
+
                    to the <i>LldR</i> dimer and free the promoter. We introduced <i>LldD</i> to increase the threshold of Lactate sensing.
+
                </p>
+
            </div>
+
  
            <div class="sec white">
+
<div class="sec white">
                <h2>AND GATE</h2>
+
                <p>
+
                    The AND gate is the association of both <i>NO</i> sensor and <i>AHL</i> or Lactate sensor. It is constituted by a hybrid promoter composed
+
                    of the PnorV promoter and the downstream esaboxes. Model shows that playing with <i>NorR</i> and <i>EsaR</i> production and degradation rates can allow a fine tuning of the sensor to adapt to the wished detection range.
+
                </p>
+
            </div>
+
  
            <div class="sec white">
+
<h2>CONCLUSION</h2>
                <h2>SWITCH MODULE</h2>
+
<p>Our design for Pavlov's coli creates a novel investigation tool for IBD that:</p>
                <p>
+
<ul>
                    AND gate activation triggers integrase production. Its role is to inverse the DNA strand containing
+
<li>Does not disrupt the gut microbiome</li>
                    the GFP gene.
+
<li>Can associate potential new markers of IBD pathogenesis to an established marker of IBD and memorize the event</li>
                </p>
+
<li>Allows for multiplexing</li>
            </div>
+
<li>Is flexible and easily adjustable to new potential markers due to its modular nature.</li>
 +
</ul>
  
            <div class="sec white">
+
 
                <h2>REPORTER MODULE</h2>
+
<h2>REFERENCES</h2>
                <p>
+
[1] G. Kolios, V. Valatas, S. G. Ward, Immunology <b>2004</b>, 113, 427-437.<br/>
                    the reporter module is just constituted of some esaboxes and the GFP gene. Under AHL presence, the reporter (GFP) is expressed.
+
[2] M. Schuster, D. J. Sexton, S. P. Diggle, E. P. Greenberg, Annu Rev Microbiol <b>2013</b>, 67, 43-63.<br/>
                </p>
+
[3] J. Bonnet, P. Subsoontorn, D. Endy, Proc Natl Acad Sci U S A <b>2012</b>, 109, 8884-8889.<br/>
            </div>
+
[4] H. Huang, C. Chai, N. Li, P. Rowe, N. P. Minton, S. Yang, W. Jiang, Y. Gu, ACS Synth Biol <b>2016</b>.<br/>
      </div>
+
[5] B. Zetsche, J. S. Gootenberg, O. O. Abudayyeh, I. M. Slaymaker, K. S. Makarova, P. Essletzbichler, S. E. Volz, J. Joung, J. van der Oost, A. Regev, E. V. Koonin, F. Zhang, Cell <b>2015</b>, 163, 759-771.<br/>
 
</div>
 
</div>
<div class="sec light_grey" id="conclusion">
+
</div>
        <div>
+
</div>        
            <h1>CONCLUSION</h1>
+
<p>One major challenge in synthetic biology is the difficulty to combine modular frameworks into higher order networks that are reliably reproducible. We designed our circuit as interchangeable, easily tuneable parts. This allows multiplexing, one of our circuit’s major advantages for a non-invasive, modular, multiplexing, in vivo tool to investigate IBD’s unknown causes.
+
 
+
</p>
+
        </div>
+
    </div>
+
  
       
 
   
 
 
</body>
 
</body>
 
</html>
 
</html>
  
 
{{:Template:ETH_Zurich/footer}}
 
{{:Template:ETH_Zurich/footer}}

Revision as of 01:04, 20 October 2016

DESIGN

OVERVIEW

Inflammatory bowel disease (IBD) is an insufficiently understood chronic disease, whose increasing incidence, lack of proper treatment and diagnostic methods make it an urgent problem to solve [CITATION NEEDED]. The current methods for diagnosing IBD mainly rely on endoscopies, which are invasive and do not allow to properly characterize the microbiome of patients, believed to be implicated in pathogenesis.

We designed an alternative solution for in vivo diagnosis, using hydrogel-encapsulated Pavlov's coli. In order for Pavlov's coli to efficiently gather information on important aspects of IBD, such as inflammation and microbiome composition, we designed our system such that it consists of:

  1. A biological AND gate that allows our system to associate known IBD markers present in the gut.
  2. A switch acting as memory, which is irreversibly flipped from "OFF" to "ON" if both markers are simultaneously detected by the AND gate. This switching mechanism renders a reporter (GFP, see later) sensitive to one of the two biomarkers previously encountered by our logic AND gate.
  3. Information sensed by the AND gate is stored (remembered) by the reporter via the switching mechanism and can be read-out later in a laboratory. This conditional activation of our reporter justifies the name of our diagnostic tool - Pavlov's coli.

The encapsulation should allow for diffusion of molecules, while preventing our bacteria from colonizing the gut, therefore providing a non-invasive tool, which does not disrupt the microbiome.

Fig. 1: Structure of Pavlov's coli's genetic circuit. (1) The sensor module comprises an AND gate which associates an inflammation marker with a candidate marker, representative of microbiome composition. (2) The switch module consists of an irreversible genetic switch. (3) The reporter module can be used to retrieve information about the biomarkers sensed by our AND gate.

An additional feature of our system is that it allows for multiplexing, meaning processing multiple signals through one channel: in our system, the reporter module (3) is activated by one of the two markers also required to activate the sensor module, i.e. the AND gate (1) (see Fig. 1). The architecture of our system has the following implication: a suite of bacterial populations, each responsive to different IBD-relevant candidate markers (e.g. different AHL molecules, lactate, etc.) as well as to an inflammation marker (e.g. NO), can be engineered, complexed together and administered to a patient; upon recovery, re-exposure of faecal samples to a previously encountered biomarker can be read out through our reporter module (see Fig. 2).

Fig. 2:Mode of action of Pavlov's coli. Step 1: After administration of our bacteria, biological markers can be sensed in the gut through a logical AND gate; the event is memorized through a switching mechanism. Step 2: Following excretion and retrieval of our bacteria, the memory can be read-out by exposing the samples containing our bacteria to a host of IBD-relevant candidate markers.

Therefore, Pavlov's coli holds promise as a non-invasive, modular, multipleable, in vivo diagnostic tool for IBD investigation.

Sensing in the gut

One major challenge in synthetic biology is the difficulty to combine modular frameworks into higher order networks that remain reliable. We designed our circuit as interchangeable, easily tunable parts, each of which is backed by a computer model and experimental data.

IBD is normally accompanied by severe inflammation of the intestine. Several sources in the literature report on a sharp increase in Nitric Oxide (NO) levels in inflamed areas. Based on this, we chose to incorporate a sensor for NO as part of a logic AND gate in our engineered bacteria[1].

Along with the presence of NO, Pavlov's coli's logic gate requires a second input in order to activate an irreversible switch (see Fig. 1; also, see section below). As the second input, we chose a marker which can provide information on microbiome composition: AHL. A number of AHLs have been found to be informative as to specific functions (e.g. biofilm formation) and microbiome composition [2]. (GIVE EXAMPLE OF AHL)

In an alternative design, we chose to replace the AHL sensor with lactate sensor. In an interview with an expert on IBD, Prof. Lacroix (LINK TO HP PAGE), we discussed the potential of bacterial metabolites as an alternative microbiome marker. One such a candidate turned out to be lactate, which is produced and metabolized by different bacteria in the gut. Although it is not as informative as AHL to the end of microbiome characterization, there is a strong interest in developing methods for lactate detection in the gut. Due to its nature as an intermediate metabolite, it is currently not possible to measure lactate concentrations in fecal samples of patients, adding appeal to the development of Pavlov's coli.

DETAILED IMPLEMENTATION

Our system is composed of a logic AND gate, a switch and a reporter, behaving together as an associative learning circuit.

The AND gate is composed of the PnorV promoter and an operator. The promoter can be activated by NorR upon its binding with NO. In the absence of NO NorR behaves as a repressor. The operator is either an esabox, for AHL sensing, or LldO, for lactate sensing. These operators are repressed by EsaR and LldR respectively and repression is relieved upon binding of AHL or lactate respectively (see Fig. 3). The modular nature of our system allowed us to easily exchange the esabox with LldO, through one site-directed mutagenesis.

The switch module, under the control of the AND gate, is responsible for flipping a reporter cassette irreversibly. We have designed three different switches, based on integrases[3], CRISPR/Cas9[4] and a novel genetic switch based on the recently discovered CRISPR/Cpf1[5](see Fig. and LINK)

The reporter module can drive expression of two different fluorescent proteins. In its default OFF state, i.e. prior to AND gate activation, the module expresses the orange fluorescent protein mNectarine under control of an operator (esabox or LldO). Upon successful flipping, activation of the operator results in GFP expression (see Fig. 3). This mechanism is what makes multiplexing possible. Note that several reporter plasmids are present in the cell and the fraction of flipped cassettes can give us quantitative information on the signal intensity of the inputs activating the AND gate (link to switch modeling page).

We chose E. coli as a host organism because it is easy to manipulate and engineer. In future the system could be transferred into a Lactobacillus acidophilus or Lactococcus lactis host, which are regarded as safe to ingest, this was recommended to us by Prof. Gerhard Rogler (LINK TO HP PAGE).

Fig. 3:Structure of our genetic circuit for IBD diagnosis. Note how NO and AHL are both necessary to express a molecular switch (here: Bxb1) which in turn is responsible for flipping a reporter cassette to its ON state, i.e. GFP can be expressed upon induction with AHL. Note that failure to activate the AND gate would result in mNectarine expression upon induction with AHL.

CONCLUSION

Our design for Pavlov's coli creates a novel investigation tool for IBD that:

  • Does not disrupt the gut microbiome
  • Can associate potential new markers of IBD pathogenesis to an established marker of IBD and memorize the event
  • Allows for multiplexing
  • Is flexible and easily adjustable to new potential markers due to its modular nature.

REFERENCES

[1] G. Kolios, V. Valatas, S. G. Ward, Immunology 2004, 113, 427-437.
[2] M. Schuster, D. J. Sexton, S. P. Diggle, E. P. Greenberg, Annu Rev Microbiol 2013, 67, 43-63.
[3] J. Bonnet, P. Subsoontorn, D. Endy, Proc Natl Acad Sci U S A 2012, 109, 8884-8889.
[4] H. Huang, C. Chai, N. Li, P. Rowe, N. P. Minton, S. Yang, W. Jiang, Y. Gu, ACS Synth Biol 2016.
[5] B. Zetsche, J. S. Gootenberg, O. O. Abudayyeh, I. M. Slaymaker, K. S. Makarova, P. Essletzbichler, S. E. Volz, J. Joung, J. van der Oost, A. Regev, E. V. Koonin, F. Zhang, Cell 2015, 163, 759-771.

Thanks to the sponsors that supported our project: